Retatrutide dose escalation in the published trials posts 151–160

Anyone deciding on the basis of what is published should know that what is published is a phase 2 programme and some pharmacokinetics. That is a genuinely early evidence base and this page will say so until it changes.

Where the retatrutide dose escalation reasoning breaks down for me is the step from the group result to the individual case. That step is almost never argued for.

Building on post #152 rather than restating it.

A note on scope: what I am saying about retatrutide dose escalation applies to the case in the first post and I would not extend it further without checking.

What we do not know about retatrutide, listed explicitly: long-term safety, real-world response rates, the dose response in diverse populations, whether the heart-rate signal persists or attenuates, durability of effect on withdrawal, efficacy in comorbidities beyond obesity.

Retatrutide dose escalation has been discussed here with more heat than it deserves, mostly because two definitions have been in play the whole time.

Answering the question post #154 raises rather than the one it answers.

The most useful thing anyone has posted about retatrutide dose escalation in this category was a table of what had been measured and by whom. That is what I would want again.

Good question, well framed, and I would like to see it answered properly.

Mass and identity: a report on retatrutide should state the mass detected by LC-MS, not assume a theoretical mass. The theoretical mass is not published in peer-reviewed literature for retatrutide at present.

Posted with less confidence than the sentence structure implies.

Post #156 is right about the mechanism and I think understates the practical bit.

Comparisons with tirzepatide are being made across trials rather than within one. Different populations, different durations, different endpoints; the effect sizes are not commensurable and nobody has run the head-to-head.

Adding the caveat now so it does not have to be extracted later.

No phase 3 results exist for retatrutide. Anything attributed to a completed phase 3 trial of this compound is either a misreading or an invention, and the honest answer to most questions here is that the data is not in yet.